This comprehensive study aggregates data from randomized controlled trials (RCTs) conducted over nearly four decades, reflecting the breadth of research spanning from 1985 through 2024. The researchers embarked on an ambitious quest, meticulously scouring six English and four Chinese academic databases to identify trials that evaluated the effects of neuroregulatory interventions on patients diagnosed with psychiatric disorders, confirmed by internationally recognized diagnostic systems including the ICD-11 and DSM-5. The inclusion criterion centered on studies that applied neuromodulation techniques explicitly aiming to regulate not just psychiatric symptoms but also body weight parameters.

From this extensive literature search, ten eligible RCTs were identified, collectively involving 528 patients diagnosed with a spectrum of psychiatric conditions including eating disorders, schizophrenia, and major depressive disorder. This diverse patient population allowed for a multifaceted examination of neuroregulatory interventions across different diagnostic categories. The meta-analysis primarily focused on quantifiable outcomes related to BMI and body weight, employing Hedges’ g as the standardized effect size metric to enable robust comparisons across heterogeneous study designs.

Crucially, the analysis revealed substantial heterogeneity among the included studies, as evidenced by I² statistics exceeding 70% for both BMI and body weight outcomes. Such high heterogeneity underscores the variability in study populations, intervention modalities, and measurement techniques, which collectively complicate the extraction of definitive conclusions. Despite this variability, the pooled effect sizes did not demonstrate statistically significant reductions in BMI or body weight attributable to neuroregulatory interventions, challenging prior assumptions about the potential dual benefits of these therapies.

The absence of significant impact on weight parameters highlights an intriguing dissociation between the neurological modulation of psychiatric symptoms and metabolic regulation. While neuromodulation techniques like TMS have been shown to influence neural circuits implicated in mood and cognition, their capacity to effect systemic physiological changes such as weight modulation appears limited, at least within the parameters and study durations analyzed. This invites further exploration into the neurobiological mechanisms underlying weight regulation in mentally ill populations and whether these mechanisms can be targeted more effectively.

Moreover, the meta-analysis underscores the methodological challenges inherent in studying complex interactions between neuropsychiatric interventions and somatic outcomes. Variations in trial duration, intensity and frequency of neuromodulation sessions, and adjunct pharmacotherapies may all impact outcomes. The studies included showed considerable diversity in these factors, which likely contributed to inconsistent findings and the observed heterogeneity. Future research might benefit from standardized protocols and longer follow-up to fully elucidate any delayed or cumulative effects on weight.

Importantly, the study authors advocate for caution in interpreting current findings as conclusive. The limited number of high-quality RCTs, combined with relatively small sample sizes and short follow-up periods, restricts the statistical power necessary to detect subtle or long-term impacts on body weight. As such, neuroregulatory interventions cannot yet be recommended as viable strategies for weight management in psychiatric populations, a domain where metabolic side effects of psychotropic medications often pose significant health risks.

This meta-analysis also invites reflection on the broader clinical implications. Psychiatric patients frequently experience weight gain due to medication side effects, lifestyle factors, and the pathophysiology of mental illness itself. While neuroregulatory techniques may offer symptom relief, addressing metabolic health remains a critical unmet need. Integrative treatment models that combine neuropsychiatric care with targeted metabolic interventions might prove more effective in improving overall patient outcomes.

Technologically, the field of neuromodulation continues to advance rapidly, with emerging modalities such as transcranial direct current stimulation (tDCS) and non-invasive vagus nerve stimulation showing promise. Future trials incorporating these novel techniques may provide richer insights into the potential for modulating neural circuits governing appetite, metabolism, and energy expenditure. Additionally, leveraging neuroimaging and biomarker studies could help identify patient subgroups more likely to benefit from combined neuroregulatory and metabolic interventions.

In summary, this meta-analysis provides a critical appraisal of the current evidence base surrounding the impact of neuroregulatory interventions on weight in patients with mental illness. Despite the theoretical appeal and clinical hope vested in these technologies, the findings indicate that, as of now, they do not produce significant changes in BMI or body weight. This highlights an urgent need for more rigorous, large-scale RCTs with extended follow-up periods to unravel the complex interplay between brain modulation and metabolic regulation.

The study serves as a clarion call for the scientific community to deepen investigations into integrative treatment strategies that address both the neuropsychiatric and metabolic dimensions of mental illness. Future research should emphasize methodological rigor, including standardized intervention protocols, comprehensive metabolic assessments, and the inclusion of diverse patient populations to ensure findings are broadly applicable.

As mental health care evolves towards precision medicine, understanding the nuanced effects of interventions on both brain function and systemic health will be essential. While neuroregulatory interventions have transformed aspects of psychiatric treatment, their role in managing weight remains unsubstantiated, marking an important frontier for future scientific inquiry.

This emerging knowledge not only guides clinicians in setting realistic expectations for neuromodulation therapies but also informs patients and caregivers about the current scope and limitations of these interventions. Ultimately, advancing this line of research promises to optimize therapeutic outcomes and enhance quality of life for individuals living with mental illness.

Subject of Research: The effectiveness of neuroregulatory interventions on weight management in patients with mental illness.

Article Title: Impact of neuroregulatory interventions upon weight in patients with mental illness: a meta-analysis of randomised controlled trials.

Article References:
Ren, W., Zhu, Y., Yang, R. et al. Impact of neuroregulatory interventions upon weight in patients with mental illness: a meta-analysis of randomised controlled trials.
BMC Psychiatry 25, 864 (2025). https://doi.org/10.1186/s12888-025-07328-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07328-8

In the traditional clinical practice of TMS, clinicians have largely relied on historical reports linking lesion locations to behavioral or emotional symptoms, alongside neuroimaging studies highlighting dysfunction in frontal brain regions. This approach, while successful in many cases, necessarily narrows the scope of potential targets to a limited region of the brain—primarily the dorsolateral prefrontal cortex and adjacent prefrontal neuronal networks. These sites have been repeatedly validated as effective loci to alleviate symptoms in treatment-resistant depression and related illnesses. Yet, this focus raises the question: are there modifiable, posterior brain hubs implicated in psychiatric symptoms that remain unexplored by neuromodulation?

Emerging research suggests that the brain is a deeply interconnected organ, with psychiatric disorders reflecting dysfunction not only in frontal executive circuits but also in posterior regions such as the occipital cortex, precuneus, inferior parietal lobules, and cerebellum. These areas, traditionally associated with perceptual processes, self-referential thought, spatial cognition, and motor control, have gained recognition for their involvement in mood regulation, attention, and cognitive integration. Despite this, they have been conspicuously understudied as possible TMS targets in clinical trials, leaving a gap in both our understanding of neuropsychiatric circuitry and the full therapeutic potential of TMS.

In a timely and insightful Perspective article, McCalley and colleagues illuminate the landscape of posterior brain targets in neuropsychiatric disorders and propose an expansion of TMS paradigms. They argue that broadening target selection to incorporate these posterior regions could unlock novel therapeutic avenues that engage distinct neural networks, potentially offering relief for patients who are resistant to conventional prefrontal stimulation. This shift necessitates both a careful examination of the functional neuroanatomy involved and rigorous testing of safety and efficacy in future clinical settings.

The occipital cortex, long associated primarily with visual processing, has recently been implicated in affective disorders due to its connectivity with limbic and frontal brain regions. Neuroimaging studies have demonstrated altered activity patterns in the occipital lobe in individuals with depression and anxiety, revealing hyperconnectivity or hypoconnectivity that correlates with symptom severity. Targeting the occipital cortex with TMS could modulate early sensory processing, which in turn might influence higher-order cognitive and emotional circuits. Such an approach challenges the traditional focus on “executive” regions and underscores the role of sensory information processing in mood regulation.

Equally compelling is the precuneus, a central node in the default mode network (DMN), known for its role in self-referential thinking, episodic memory retrieval, and conscious awareness. Aberrant DMN activity has been robustly linked to depressive rumination and other maladaptive cognitive patterns seen in psychiatric illnesses. The precuneus’s accessibility to magnetic stimulation offers a tantalizing target to reshape network dynamics associated with negative self-focus, potentially alleviating persistent depressive symptoms or anxiety disorders. Early pilot studies hint at the feasibility of modulating this region noninvasively, though comprehensive clinical trials are warranted.

The inferior parietal lobules represent another posterior cortical area that holds therapeutic promise. These brain regions integrate multisensory information and contribute to attentional control and sensorimotor integration. Dysfunctions here have been observed in schizophrenia and mood disorders, where patients manifest aberrant perception, attentional bias, or impaired reality monitoring. By leveraging TMS to recalibrate activity in the inferior parietal lobules, clinicians may restore balance within distributed cortical networks, improving both cognitive and affective symptoms. However, the intricacy of this region’s functions requires precise targeting and modulation protocols to avoid undesired side effects.

Perhaps most intriguingly, the cerebellum—a structure historically relegated to motor coordination—has surfaced as a critical player in the regulation of emotion and cognition. The cerebellum is richly interconnected with the prefrontal cortex, limbic system, and associative sensory areas, and its involvement in psychiatric disorders such as depression, bipolar disorder, and autism spectrum conditions is increasingly recognized. Preliminary TMS studies have begun to explore cerebellar stimulation, noting possible benefits in mood stabilization and cognitive enhancement. This new frontier of neuromodulation could redefine therapeutic boundaries and challenge preconceived notions of localized brain function.

While posterior TMS targets offer exciting prospects, several technical and safety considerations must be addressed in their clinical implementation. The unique neuroanatomy and deeper cortical positioning of some posterior regions necessitate refined coil designs and stimulation parameters to achieve effective yet safe neuromodulation. In addition, the functional heterogeneity within posterior regions requires careful mapping to avoid off-target effects that could exacerbate symptoms or trigger unintended cognitive disruptions. Long-term studies will be critical to establish optimal dosing, session frequency, and durability of therapeutic gains.

Another challenge lies in integrating multi-modal imaging techniques, such as functional MRI, diffusion tensor imaging, and magnetoencephalography, to accurately identify suitable posterior targets based on individual neurocircuitry profiles. Personalized medicine approaches, combining advanced neuroimaging with computational modeling of electromagnetic field distribution, could tailor TMS protocols to each patient’s unique brain architecture. This precision medicine paradigm promises to maximize efficacy while minimizing adverse effects, heralding a new age in psychiatric treatment.

The few existing clinical trials investigating posterior TMS targets have yielded encouraging but preliminary results. Some studies targeting the occipital cortex have shown improvements in visual processing and mood symptoms, while cerebellar stimulation has demonstrated potential in enhancing executive function and reducing anxiety. These nascent data suggest that posterior TMS might complement or, in some cases, surpass traditional prefrontal approaches, especially for patients with resistant or atypical presentations. Nonetheless, replication in larger, randomized controlled studies remains an essential next step.

Combining posterior TMS targets with established prefrontal stimulation protocols could provide synergistic effects by engaging both sensory and executive neural networks. Multi-site stimulation paradigms might modulate dysfunctional connectivity more holistically than unilateral targeting, offering a richer therapeutic landscape. However, this complexity mandates careful clinical design to avoid overstimulation or desynchronization of critical neural circuits.

Ethically, expanding TMS beyond the frontal cortex compels the psychiatric community to balance innovation with caution. Given the emerging nature of posterior target research, informed consent processes must transparently communicate the experimental status of these interventions and potential unknown risks. Enhanced monitoring for adverse events and cognitive side effects will be necessary, alongside long-term follow-up to ascertain sustained benefits or late-emerging complications.

The consideration of posterior brain regions for neuromodulation reflects a broader paradigm shift in psychiatry—one that embraces the brain’s intrinsic network architecture rather than isolated loci. Modern psychiatric disorders are increasingly conceptualized as circuitopathies, involving complex interplay across distributed brain regions. TMS targeting posterior cortical and cerebellar nodes exemplifies this network-based approach, leveraging evolving neurobiological insights to refine therapeutic strategies.

In conclusion, the expansion of TMS applications to include posterior brain targets heralds a promising avenue for addressing unmet clinical needs in psychiatric treatment. While frontal lobe stimulation has established a robust therapeutic foundation, integrating occipital, parietal, precuneal, and cerebellar targets may enrich outcomes and offer new hope for patients with refractory conditions. Continued interdisciplinary collaboration among neuroscientists, clinicians, and engineers will be crucial to fully realize this potential and translate neuroanatomical discoveries into impactful, patient-centered therapies.

The contributions of McCalley et al. firmly anchor this emerging discussion in a rigorous scientific framework, emphasizing the importance of careful, methodical exploration of posterior neural hubs. Their Perspective calls on the psychiatric and neuromodulation communities to venture beyond conventional boundaries in pursuit of more comprehensive, network-oriented treatments. As research accelerates in this domain, TMS may well transform from a predominantly frontal cortex tool into an exquisite, multi-target instrument capable of reshaping the future of mental health care.

Subject of Research:
Transcranial magnetic stimulation targeting posterior brain regions for psychiatric disorder treatment.

Article Title:
Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.

Article References:

McCalley, D.M., Sanderson, L.L., Dowdle, L.T. et al. Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.
Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00433-3

Image Credits: AI Generated